InsiderTrades

Form 4 for RVMD Revolution Medicines, Inc.

Accepted 2026-09-14 18:03:59 ET · period of report 2026-09-10 · accession 0002124509-26-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-09-14 18:03 2026-09-10 RVMD Mancini Anthony See Remarks M - OptEx $33.62 +9,363 59.3K +19% +$314.8K
DMT 2026-09-14 18:03 2026-09-10 RVMD Mancini Anthony See Remarks S - Sale+OE $204.16 -15.4K 43.9K -26% -$3.15M
DT 2026-09-14 18:03 2026-09-10 RVMD Mancini Anthony See Remarks M - OptEx $0.00 -9,363 96.7K -9% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-09-10 M A 9,363 $33.62 59,338 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.
2 Common Common Stock 2026-09-10 S D 6,019 $203.28 53,319 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. (F2) The transaction was executed in multiple trades at prices ranging from $202.64 to $203.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3 Common Common Stock 2026-09-10 S D 5,530 $204.14 47,789 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. (F3) The transaction was executed in multiple trades at prices ranging from $203.64 to $204.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
4 Common Common Stock 2026-09-10 S D 2,420 $205.05 45,369 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. (F4) The transaction was executed in multiple trades at prices ranging from $204.64 to $205.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
5 Common Common Stock 2026-09-10 S D 1,179 $206.10 44,190 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. (F5) The transaction was executed in multiple trades at prices ranging from $205.85 to $206.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
6 Common Common Stock 2026-09-10 S D 300 $207.17 43,890 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. (F6) The transaction was executed in multiple trades at prices ranging from $207.12 to $207.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F7) Includes 43,700 restricted stock units.
7 Derivative Stock Option (Right to Buy) 2026-09-10 M D 9,363 $0.00 96,746 D $33.62 · — to 2035-03-31 9,363 Common Stock (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. (F8) Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.